139 related articles for article (PubMed ID: 34467575)
1. Synthesis and biological evaluation of 3,5-diaryl-pyrazole derivatives as potential antiprostate cancer agents.
Anil D; Caykoylu EU; Sanli F; Gambacorta N; Karatas OF; Nicolotti O; Algul O; Burmaoglu S
Arch Pharm (Weinheim); 2021 Dec; 354(12):e2100225. PubMed ID: 34467575
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis and Biological Evaluation of 1-methyl-1H-pyrazole-5-Carboxamide Derivatives as Novel Anti-Prostate Cancer Agents.
Chen X; Xu C; Li Y; Duan X; Zhao G
Anticancer Agents Med Chem; 2021; 21(17):2368-2378. PubMed ID: 33530916
[TBL] [Abstract][Full Text] [Related]
4. Dual EGFR/VEGFR2 inhibitors and apoptosis inducers: Synthesis and antitumor activity of novel pyrazoline derivatives.
Alkamaly OM; Altwaijry N; Sabour R; Harras MF
Arch Pharm (Weinheim); 2021 Apr; 354(4):e2000351. PubMed ID: 33252142
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of stable benzimidazole derivatives bearing pyrazole as anticancer and EGFR receptor inhibitors.
Akhtar MJ; Khan AA; Ali Z; Dewangan RP; Rafi M; Hassan MQ; Akhtar MS; Siddiqui AA; Partap S; Pasha S; Yar MS
Bioorg Chem; 2018 Aug; 78():158-169. PubMed ID: 29571113
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel 5-methyl-1H-pyrazole derivatives as potential antiprostate cancer agents: Design, synthesis, molecular modeling, and biological evaluation.
Zhang D; Asnake S; Zhang J; Olsson PE; Zhao G
Chem Biol Drug Des; 2018 Jun; 91(6):1113-1124. PubMed ID: 29388326
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents.
Lokesh BVS; Prasad YR; Shaik AB
Infect Disord Drug Targets; 2019; 19(3):310-321. PubMed ID: 30556506
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, Molecular Docking, and Anticancer Evaluation of Pyrazole Linked Pyrazoline Derivatives with Carbothioamide Tail as EGFR Kinase Inhibitors.
Nawaz F; Alam O; Perwez A; Rizvi MA; Naim MJ; Siddiqui N; Firdaus JU; Rahman S; Jha M; Sheikh AA
Anticancer Agents Med Chem; 2021; 21(1):42-60. PubMed ID: 32718297
[TBL] [Abstract][Full Text] [Related]
9. 3'-(4-(Benzyloxy)phenyl)-1'-phenyl-5-(heteroaryl/aryl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazole]-2-carboxamides as EGFR kinase inhibitors: Synthesis, anticancer evaluation, and molecular docking studies.
Nawaz F; Alam O; Perwez A; Rizvi MA; Naim MJ; Siddiqui N; Pottoo FH; Jha M
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900262. PubMed ID: 32003485
[TBL] [Abstract][Full Text] [Related]
10. New pyrimidine and pyrazole-based compounds as potential EGFR inhibitors: Synthesis, anticancer, antimicrobial evaluation and computational studies.
Othman IMM; Alamshany ZM; Tashkandi NY; Gad-Elkareem MAM; Anwar MM; Nossier ES
Bioorg Chem; 2021 Sep; 114():105078. PubMed ID: 34161878
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of 3-(4-fluorophenyl)-1H-pyrazole derivatives as androgen receptor antagonists.
Guo G; Liu J; Wang G; Zhang D; Lu J; Zhao G
Anticancer Drugs; 2016 Apr; 27(4):278-85. PubMed ID: 26633887
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis, and Biological Evaluation of Novel Thiazolyl Substituted Bis-pyrazole Oxime Derivatives with Potent Antitumor Activities by Selectively Inducing Apoptosis and ROS in Cancer Cells.
Xiong B; Chen S; Zhu P; Huang M; Gao W; Zhu R; Qian J; Peng Y; Zhang Y; Dai H; Ling Y
Med Chem; 2019; 15(7):743-754. PubMed ID: 30147012
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of novel 3,5-diaryl pyrazole derivatives using combinatorial chemistry as inhibitors of tyrosinase as well as potent anticancer, anti-inflammatory agents.
Bandgar BP; Totre JV; Gawande SS; Khobragade CN; Warangkar SC; Kadam PD
Bioorg Med Chem; 2010 Aug; 18(16):6149-55. PubMed ID: 20638287
[TBL] [Abstract][Full Text] [Related]
14. Novel Pyrazoloquinolin-2-ones: Design, synthesis, docking studies, and biological evaluation as antiproliferative EGFR-TK inhibitors.
Elbastawesy MAI; Aly AA; Ramadan M; Elshaier YAMM; Youssif BGM; Brown AB; El-Din A Abuo-Rahma G
Bioorg Chem; 2019 Sep; 90():103045. PubMed ID: 31212178
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and in vitro biological evaluation of novel pyrazole derivatives as potential antitumor agents.
Christodoulou MS; Fokialakis N; Nam S; Jove R; Skaltsounis AL; Haroutounian SA
Med Chem; 2012 Sep; 8(5):779-88. PubMed ID: 22741785
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
Bakr RB; Mehany ABM; Abdellatif KRA
Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, Cytotoxicity Evaluation, Molecular Docking and Utility of Novel Chalcones as Precursors for Heterocycles Incorporating Pyrazole Moiety.
Gomha SM; Abdallah MA; Abbas IM; Kazem MSH
Med Chem; 2018; 14(4):344-355. PubMed ID: 29065841
[TBL] [Abstract][Full Text] [Related]
18. New Approaches for the Synthesis of Fused Thiophene, Pyrazole, Pyran and Pyridine Derivatives with Anti-Proliferative Together with c-Met Kinase and Prostate Cancer Cell Inhibitions.
Mohareb RM; Milad YR; El-Ansary RA
Anticancer Agents Med Chem; 2021; 21(13):1751-1766. PubMed ID: 33176664
[TBL] [Abstract][Full Text] [Related]
19. Pyrazole derivatives as potent EGFR inhibitors: synthesis, biological evaluation and
Bayoumi NA; El-Shehry MF
Future Med Chem; 2022 Dec; 14(23):1755-1769. PubMed ID: 36524436
[No Abstract] [Full Text] [Related]
20. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
